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SUMMARY.-This study indicated that: (1) i.p. inoculation of protamine into
(Rauscher) leukemic mice increased their 9deathtime,(2) protamine was more
toxic for leukemic than normal mice and (3) the in vitro reaction between
Rauscher virus and protamine reduced its infectivity for mice.
PROTAMINE complexes with nucleic acid in the sperm of salmon (salmine) and
other fish (Kay, 1966). In mice it inhibited the growth of Landschutz ascites
and sarcoma 180 tumors (Muggleton, MacLaren and Dyke, 1964). However,
in vitro incubation of N.J.A. leukemic cells with protamine before inoculation
into mice failed to inhibit the development ofleukemia (Larson and Olson, 1968).
Our study investigated what effects protamine had on Rauscher virus induced
murine leukemia and, in a separateexperiment, Rauscher virus infectivity in mice
after in vitro incubation with protamine.
MATERIALS AND METHODS
In the following experiments all dilutions were made in phosphate (0-01m)
buffered saline (0-15m) pH 7-4 (PBS) and BALB/c/Tex inbred mice were utilized.
In vivo 8tudim
Day-old mice were inoculated intraperitoneally (i.p.) with 0-05 of a suspension
containing 50-100MLD50 of Rauscher leukemia virus (MLD50 minimum
concentration ofviruskilling50% oftestmice). Whenpost inoculationmortality
and hepatosplenomegaly were present, mice were divided into subgroups. Then
leukemic mice in a subgroup were each inoculated i.p. three times per week for
6 weeks with one of the following concentrations of protamine sulfate/10 g. of
body weight: (1) 0-2 mg., (2) 0-4 mg., (3) 0-6 mg. and (4) 1-0 mg. Control mice,
the same age, consisted of: (1) normal noninoculated, isolated, (2) normal, isolated
and inoculated with 1-0 mg. of protamine as described above, and (3) leukemic
(viral controls). All mice were observed up to 120 days with mortality recorded
daily and necropsies done on those which expired.
In vitro studies
Rauscher virus and protamine were mixed in such a manner that the viral
concentration/0-05 ml. was 50-100MLD50 and protamine in one of the following
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concentrations: (1) 0-025 mg., (2) 0-05 mg., (3) 0-1 mg. The mixtures were
reacted at 20' C. for 30 minutes. Each was then centrifuged at 25,000 r.p.m.
for 15 minutes at 4' C. The supernatant was decanted off and recentrifuged.
The second and first sediments were pooled. These pooled sediments and the
second supernatant were diluted with PBS to the original volume. Then undilu-
ted, 10-1, 10-2 andlo-3concentrations wereprepared in PBS and each inoculated
i.p. (0-05 ml.) into a group ofday-old mice. Controls consisted ofday-old mice:
(1) inoculated i.p. with Rauscher virus (centrifuged and prepared as described
above) incubated, (2) inoculatedi.p. with 0
-1, 0
-05 or 0
-025mg. ofprotamine and
(3) normal mice held 60 days for splenic comparison. Mice were observed for 60
days and necropsies done on those which expired 48 hours after inoculation.
Mortality after thisperiod was used fordetermining MLD,50 values. Survivors at
60days werenecropsied and the presenceofsplenomegalyrecorded (Friend, 1957).
Splenomegalyandmortality wereusedindeterminingSD50values(SD50=minimum
concentration ofvirusinducingsplenomegaly in50% oftestedmice). Preliminary
studies showed that spleens of 60-day-old normal mice weighed 250 + 50 mg.;
therefore, spleens over 300 mg. were considered pathological and used in SD50
calculations.
RESULTS
The maximum concentration of protamine sulfate used (Table 1) was deter-
mined from a study which indicated that 1 mg. of protamine sulfate/10 g. body
weight given i.p. was toxic for erythroleukemic mice. These mice expired 1-4
hours after injection. At necropsy, their livers, spleens and lymph nodes were
necrotic andhemorrhagic. Mortality or similar lesions were not evident in normal
mice.
TABLEI.-ProtamineSulfate's Effect on Mean (X) Death Time of Mice Infected
with Viral (Rauscher) Leukemia
Amount No. of No. of X Death
Group (mg.) mice expirationst (days)§
NorniaJs 100 5/loot N.S.M.11 Nornials plus Protaimne 1-0 25 0/25 N.S.M.
Leukemic* (viral controls) 50 50/50 40
Leukemic plus protamine 0- 2 40 40/40 50
Leukemic plus protamine 0-4 40 40/40 54
Leukemic plus protamine 0-6 30 28/30T 78
Leukemic plus protamine 1-0 22 22/22 39
Inoculated with Rauscher virus (no protamine).
t No. ofexpirations/No. of mice in group. t Normal colony mortality over 3-5 months was 1-5%. § Calculated from day of viral inoculation (day 1) until death.
11 N.S.M. = no significant mortality.
T 2 mice were still alive at 120 days.
At necropsy, the viral controls showed enlarged spleens, livers and ascites.
Deaths occurred 30-45 days post inoculation with a X death time of 40 days. Leukemic mice inoculated with 0.2 or 0.4 mg. ofprotamine had greater survival
timesthantheleukemiccontrols, butlittle evidence oftumorregression. Whereas, leukemic mice inoculated with 0-6 mg. of protamine showed little ascites after 2
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hadregressed. Mice which survived 120 days had no gross evidence ofleukemia;
however, microscopic examination ofthe spleens, livers and lymph nodes showed
the presence ofleukemic cells.
TABLE II.-Results Obtained when the Rauscher Virus was Incubated In Vitro
at 20' C.for 30 Minutes with Various Concentrations ofProtamine
Protamine (mg.)*
A
0- 025 0.05 0.1
Specimen MLD50 SD50 MLD50 SD50 MLD50 SD50
Supematant 41t 120 11 39 1 10
Sediiinent 10 24 10 31 1 10
Controls MLD50 SD50
1. Virus-no incubation 62 210
supernatant 62 210
sediment . I 10
2. Virus-incubation
supernatant 56 190
sediment. 1 10
3. Protamine-alone
0- I mg. 0 0
0.05mg.
. 0 0
0-025 mg.
. 0 0
Concentration of protamine/0
- 05 ml. incubated with 50-100 MLD 50 of virus.
t Values are the reciprocal of dilutions containing I MLD50 or 1 SD50, i.e. number ofMLD50 or
SD50 in undiluted specimens. Calculations were based upon a standard method (Reed and Muench,
1938).
Preliminary studies indicated that in vitro incubation of virus and protamine
at 20' C. for 30 minutes gave the most reproducible results, and therefore, was
used in this study. The concentrations of protamine reacted in vitro with the
Rauscher virus were based upon weight ratios (average weight ofnewborn-I g.), andapproximated those described in Table I. The averageweight ofspleens used
for SD50 calculations was 650 mg. with a range of 315-2200 mg. Necropsies
on the viral control mice and those inoculated with virus and protamine which
expired before 60 days showed gross lesions similar to those described under
Tablel. ControlmiceinoculatedwithO-Img.,0-05mg.orO-025mg.ofprotamine showed no mortality or evidence ofhepatosplenomegaly.
DISCUSSION
Ourstudyindicatedthatintraperitonealinoculation ofprotamine intoleukemic
mice prolonged their 1 death time and the in vitro reaction ofprotamine and the
Rauscher murine leukemia virus reduced its infectivity for mice. The nature of
neither inhibition was determined. Studiesby otherssuggestedpossible modes of
action.
One inhibitor of murine leukemia viruses is interferon (Isaacs andLinderman,
1957). Administered passively, it inhibited the in vivo development of viral
(Friend) murine leukemia (Gressler et al., 1967). These viruses are also inhibited
in vivo by treatment with interferon inducing synthetic products (Padman, et al.,
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However, leukemia susceptible adultBALB/c mice whichproducedhigh inter-
feron levels after non-leukemia viral induction, produced lower levels after
Rauscher virus inoculation (Peries, Boiron and Canivet, 1965; Glasgow and
Friedman, 1969). In contrast leukemia resistant adult CD-1 mice inoculated with
Rauscher virus developed higher serum levels of interferon than BALB/c mice
(GlasgowandFriedman, 1969). Thissuggested arelationshipbetweenresistance to
murine leukemia andinterferonproduction. Inthe caseofprotamine, itsability to
induce orpotentiate interferonproduction in leukemic mice must be considered.
Nucleohistones (Bonner and T'so, 1966) are considered inducers or potentia-
tors of interferon's cellular reactions (Stan'ek and Matisova', 1968), and therefore
it is possible that in our study protamine (a nucleohistone) may have induced or
potentiated interferon production in leukemic mice. If so, mice infected for
25-30 days with Rauscher virus produced interferon(s) effective after the onset
of clinical disease and in a system inhibitory to interferon production (Glasgow
and Friedman, 1969). Present knowledge of interferons does not indicate such
a possibility; therefore, other modes were considered. Interference with viral
replication was one (Li eat al., 1963). Protamine is known to react with viruses
in vitro and reduce their infectivity (Warren et al., 1949). Our study indicated
that the in vitro reaction between Rauscher virus and protamine reduced its
infectivityformice. However, itisnotknownwhetherthisinteractionwasinvolved
in the in vivo inhibition ofthis virus.
The above studies suggested that protamine inhibited viral replication by
inducing interferon production or reacted directly on the
" complete
" leukemia
virus. These considerations concerned the leukemic process in the host. Know-
ledge of protamine's other effects in vivo should be considered. Protamine at
2 mg.110 g. body wt was toxic for normal mice (Yartiainen and Marble, 1941).
At I mg./10 g. body wt we found it toxic for erythroleukemic mice. Such
toxicity may be related to its anticoagulative effect (Waldschmidt-Leitz, Stadler
and Steigerwaldt, 1929).
We postulated that leukemic cells with a higher negative surface charge than
normal cells (Ambrose, James and Lowick, 1956) concentrated in the liver and
spleen. Interaction with protamine caused a local excess ofprotamine in these
tissues.
This excess removed from blood filtering through these organs a coagulative
factor, such as V in man, which is removed in vitro by an excess of protamine
(Britten, 1965). Our evidence for this occurrence was the hemorrhagic state of
the internal organs of mice given a toxic dose ofprotamine.
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